
Source briefing
Country report: ECDC Public Health Emergency Preparedness Assessment for the Czech Republic, 2026
The aim of the Public Health Emergency Preparedness Assessment, as mandated in Article 8 of Regulation (EU) 2022/2371 on serious cross-border threats to health, is to improve prevention, preparedness and response planning in European Union/European Economic Area (EU/EEA)…
Read →
Source briefing
Protocol for the carbapenem-resistant Enterobacter cloacae complex (CRECC) pilot survey
The primary EU-level public health objective of the CRECC pilot survey is to determine the occurrence, geographical distribution and population dynamics of high-risk CRECC lineages, and related transmissible genetic elements of public health importance, within healthcare settings in…
Read →
Source briefing
Qualification of novel methodologies for medicine development (QoNM)
Qualification of novel methodologies for medicine development (QoNM)
Read →
Source briefing
Qualification of novel methodologies for medicine development: Letters of support
Qualification of novel methodologies for medicine development: Letters of support
Read →
Source briefing
Qualification of novel methodologies for medicine development: CHMP qualification opinions
Qualification of novel methodologies for medicine development: CHMP qualification opinions
Read →
Source briefing
Comparative effectiveness of amlodipine versus nifedipine prescribed at discharge in patients with ischemic stroke or transient ischemic attack: A nationwide 5-year follow-up registry study
by Xinya Li, Xue Xia, Meng Gao, Qin Xu, Yijun Zhang, Jing Jing, Yi Zhai, Xia Meng, Anxin Wang Background Amlodipine and nifedipine are the most commonly prescribed calcium channel blockers (CCB) for patients suffering from ischemic stroke…
Read →
Source briefing
Human medicines European public assessment report (EPAR): Roclanda, latanoprost / netarsudil, Date of authorisation: 07/01/2021, Revision: 13, Status: Authorised
Human medicines European public assessment report (EPAR): Roclanda, latanoprost / netarsudil, Date of authorisation: 07/01/2021, Revision: 13, Status: Authorised
Read →
Source briefing
Human medicines European public assessment report (EPAR): Rhokiinsa, netarsudil, Date of authorisation: 19/11/2019, Revision: 8, Status: Authorised
Human medicines European public assessment report (EPAR): Rhokiinsa, netarsudil, Date of authorisation: 19/11/2019, Revision: 8, Status: Authorised
Read →
Source briefing
Human medicines European public assessment report (EPAR): Casgevy, exagamglogene autotemcel, Date of authorisation: 09/02/2024, Revision: 7, Status: Authorised
Human medicines European public assessment report (EPAR): Casgevy, exagamglogene autotemcel, Date of authorisation: 09/02/2024, Revision: 7, Status: Authorised
Read →
Source briefing
Human medicines European public assessment report (EPAR): Etcamah, camizestrant, Date of authorisation: 20/07/2026, Status: Authorised
Human medicines European public assessment report (EPAR): Etcamah, camizestrant, Date of authorisation: 20/07/2026, Status: Authorised
Read →